Javier Cortes Selected Research

eribulin

6/2021	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.
7/2020	High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
1/2020	Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.
1/2020	Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis.
5/2019	The safety of eribulin for the treatment of metastatic breast cancer.
11/2018	Multiple modes of action of eribulin mesylate: Emerging data and clinical implications.
1/2018	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
1/2016	Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.
12/2015	"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.
12/2015	Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Javier Cortes Research Topics

Disease

85	Breast Neoplasms (Breast Cancer) 08/2022 - 03/2007
45	Neoplasms (Cancer) 10/2022 - 04/2007
17	Triple Negative Breast Neoplasms 10/2022 - 10/2014
8	Disease Progression 05/2021 - 03/2010
7	Diarrhea 07/2022 - 12/2015
7	Neoplasm Metastasis (Metastasis) 01/2020 - 10/2014
6	Fatigue 05/2021 - 03/2011
6	Neutropenia 05/2021 - 03/2011
5	Pathologic Complete Response 01/2020 - 02/2015
4	Nausea 07/2022 - 04/2012
3	Vomiting 07/2022 - 12/2015
3	Cardiotoxicity 09/2021 - 01/2009
3	Hypoxia (Hypoxemia) 06/2021 - 03/2017
3	Peripheral Nervous System Diseases (PNS Diseases) 03/2017 - 03/2011
2	Interstitial Lung Diseases (Interstitial Lung Disease) 07/2022 - 01/2020
2	Leukopenia 07/2022 - 05/2021
2	Pneumonia (Pneumonitis) 07/2022 - 11/2015
2	Exanthema (Rash) 05/2021 - 10/2020
2	Sepsis (Septicemia) 01/2021 - 11/2015
2	Hypertension (High Blood Pressure) 01/2020 - 10/2014
2	Brain Neoplasms (Brain Tumor) 04/2018 - 01/2003
2	Melanoma (Melanoma, Malignant) 01/2018 - 12/2015
2	Circulating Neoplastic Cells 01/2018 - 12/2015
2	Asthenia 10/2017 - 03/2011
2	Headache (Headaches) 10/2017 - 12/2015
2	Alopecia (Baldness) 12/2015 - 04/2012
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2004 - 01/2003
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Pancytopenia 01/2021
1	Shock 01/2021

Drug/Important Bio-Agent (IBA)

19	eribulin FDA Link 06/2021 - 04/2010
18	Hormones (Hormone)IBA 08/2022 - 11/2009
15	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2013
14	ErbB Receptors (EGF Receptor)IBA 08/2022 - 11/2009
14	Trastuzumab (Herceptin)FDA Link 07/2022 - 04/2007
12	AnthracyclinesIBA 11/2021 - 09/2010
10	Paclitaxel (Taxol)FDA LinkGeneric 10/2022 - 01/2003
10	taxaneIBA 01/2021 - 09/2010
9	human ERBB2 proteinIBA 07/2022 - 03/2010
8	Capecitabine (Xeloda)FDA Link 05/2021 - 09/2010
6	Carboplatin (JM8)FDA LinkGeneric 10/2022 - 12/2015
6	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 06/2007
6	pembrolizumabIBA 10/2022 - 01/2020
6	pertuzumabIBA 01/2019 - 03/2010
5	Estrogen ReceptorsIBA 01/2022 - 04/2015
5	Pharmaceutical PreparationsIBA 01/2022 - 04/2012
5	Proteins (Proteins, Gene)FDA Link 10/2021 - 08/2012
5	Gemcitabine FDA Link 12/2020 - 01/2003
5	Bevacizumab (Avastin)FDA Link 11/2020 - 04/2009
4	130-nm albumin-bound paclitaxelIBA 12/2020 - 12/2015
4	Monoclonal AntibodiesIBA 03/2019 - 04/2007
4	Phosphotransferases (Kinase)IBA 01/2018 - 04/2007
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 12/2019
3	abemaciclibIBA 08/2022 - 11/2020
3	Lapatinib (GW572016)FDA Link 07/2022 - 04/2007
3	Aromatase InhibitorsIBA 01/2022 - 01/2017
3	Cyclin-Dependent Kinase 4IBA 01/2022 - 09/2020
3	Taxoids (Taxanes)IBA 09/2021 - 03/2007
3	exemestane (Aromasin)FDA Link 12/2020 - 01/2017
3	Ado-Trastuzumab EmtansineIBA 01/2020 - 09/2012
3	Phenobarbital (Luminal)FDA Link 11/2018 - 01/2018
3	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 02/2014
3	Cell-Free Nucleic AcidsIBA 01/2018 - 07/2013
3	Docetaxel (Taxotere)FDA Link 02/2017 - 03/2012
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2016 - 01/2003
2	Epirubicin (Ellence)FDA LinkGeneric 10/2022 - 01/2020
2	Tamoxifen FDA LinkGeneric 08/2022 - 01/2021
2	trastuzumab deruxtecanIBA 01/2022 - 01/2020
2	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 05/2021
2	durvalumabIBA 12/2021 - 11/2020
2	sacituzumab govitecanIBA 10/2021 - 04/2020
2	liposomal doxorubicin (Doxil)FDA Link 09/2021 - 01/2009
2	enzalutamideIBA 05/2021 - 01/2018
2	Androgen Receptors (Androgen Receptor)IBA 05/2021 - 01/2018
2	Everolimus FDA Link 12/2020 - 10/2017
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 10/2020 - 04/2015
2	neratinibIBA 01/2020 - 12/2019
2	Antineoplastic Agents (Antineoplastics)IBA 05/2019 - 03/2011
2	etirinotecan pegolIBA 01/2018 - 11/2015
2	ridaforolimusIBA 10/2017 - 01/2017
2	Fulvestrant (Faslodex)FDA Link 10/2017 - 04/2015
2	dalotuzumabIBA 10/2017 - 01/2017
2	nintedanibIBA 03/2017 - 03/2017
2	Analgesics (Analgesic Drugs)IBA 10/2014 - 04/2010
2	Cisplatin (Platino)FDA LinkGeneric 06/2004 - 01/2003
1	pyrotinibIBA 07/2022
1	Letrozole (Femara)FDA LinkGeneric 01/2022
1	palbociclibIBA 01/2022
1	Tumor Biomarkers (Tumor Markers)IBA 01/2022
1	olaparibIBA 12/2021
1	glembatumumab vedotinIBA 05/2021
1	Loperamide (Imodium)FDA LinkGeneric 01/2021

Therapy/Procedure

37	Therapeutics 10/2022 - 01/2003
34	Drug Therapy (Chemotherapy) 10/2022 - 01/2003
6	Neoadjuvant Therapy 10/2022 - 11/2016
4	Immunotherapy 02/2022 - 01/2018
2	Radiotherapy 01/2020 - 01/2019
2	Aftercare (After-Treatment) 01/2018 - 10/2014
2	TP protocol 06/2004 - 01/2003
1	Drug Tapering 01/2021